AHR- and ER-Mediated Toxicology and Chemoprevention

Advances in Molecular Toxicology

Volumn 7, Issue , 2013, Pages 1-38

  Matthews, Jason ^a,b   Ahmed, Shaimaa ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b UNIVERSITY OF OSLO   (Norway)

Author keywords

2,3,7,8 Tetrachlorodibenzo p dioxin; Aryl hydrocarbon nuclear translocator; Aryl hydrocarbon receptor; Breast cancer; Crosstalk; Estrogen; Estrogen receptor; Transcription

Indexed keywords

AROMATIC HYDROCARBON RECEPTOR; CELL NUCLEUS RECEPTOR; DIOXIN; ESTROGEN RECEPTOR; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; HEPATOCYTE NUCLEAR FACTOR 3ALPHA; LIGAND; PROTEASOME;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CHEMOPROPHYLAXIS; ESTROGEN METABOLISM; HEALTH HAZARD; HUMAN; IMMUNE SYSTEM; NEGATIVE FEEDBACK; PRIORITY JOURNAL; PROMOTER REGION; TRANSACTIVATION;

EID: 84881608276     PISSN: 18720854     EISSN: None     Source Type: Book Series    
DOI: 10.1016/B978-0-444-62645-5.00001-8     Document Type: Chapter

References (203)

1. McIntosh B.E., Hogenesch J.B., Bradfield C.A. Mammalian Per-Arnt-Sim proteins in environmental adaptation. Annu. Rev. Physiol. 2010, 72:625-645.
2. Gu Y.Z., Hogenesch J.B., Bradfield C.A. The PAS superfamily: sensors of environmental and developmental signals. Annu. Rev. Pharmacol. Toxicol. 2000, 40:519-561.
3. Hankinson O. Role of coactivators in transcriptional activation by the aryl hydrocarbon receptor. Arch. Biochem. Biophys. 2005, 433(2):379-386.
4. Poland A., Kende A. 2,3,7,8-Tetrachlorodibenzo-p-dioxin: environmental contaminant and molecular probe. Fed. Proc. 1976, 35(12):2404-2411.
5. Denison M.S., Nagy S.R. Activation of the aryl hydrocarbon receptor by structurally diverse exogenous and endogenous chemicals. Annu. Rev. Pharmacol. Toxicol. 2003, 43:309-334.
6. Zhang S., Qin C., Safe S.H. Flavonoids as aryl hydrocarbon receptor agonists/antagonists: effects of structure and cell context. Environ. Health Perspect. 2003, 111(16):1877-1882.
7. Casper R.F., et al. Resveratrol has antagonist activity on the aryl hydrocarbon receptor: implications for prevention of dioxin toxicity. Mol. Pharmacol. 1999, 56(4):784-790.
8. Hahn M.E. Aryl hydrocarbon receptors: diversity and evolution. Chem. Biol. Interact. 2002, 141(1-2):131-160.
9. Walisser J.A., et al. Patent ductus venosus and dioxin resistance in mice harboring a hypomorphic Arnt allele. J. Biol. Chem. 2004, 279(16):16326-16331.
10. Schmidt J.V., et al. Characterization of a murine Ahr null allele: involvement of the Ah receptor in hepatic growth and development. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(13):6731-6736.
11. Mimura J., et al. Loss of teratogenic response to 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in mice lacking the Ah (dioxin) receptor. Genes Cells 1997, 2(10):645-654.
12. Baba T., et al. Intrinsic function of the aryl hydrocarbon (dioxin) receptor as a key factor in female reproduction. Mol. Cell Biol. 2005, 25(22):10040-10051.
13. Fernandez-Salguero P.M., et al. Aryl-hydrocarbon receptor-deficient mice are resistant to 2,3,7,8-tetrachlorodibenzo-p-dioxin-induced toxicity. Toxicol. Appl. Pharmacol. 1996, 140(1):173-179.
14. Nilsson S., Gustafsson J.A. Biological role of estrogen and estrogen receptors. Crit. Rev. Biochem. Mol. Biol. 2002, 37(1):1-28.
15. Nilsson S., Gustafsson J.A. Estrogen receptor transcription and transactivation: basic aspects of estrogen action. Breast Cancer Res. 2000, 2(5):360-366.
16. Tian Y., et al. Ah receptor and NF-kappaB interactions, a potential mechanism for dioxin toxicity. J. Biol. Chem. 1999, 274(1):510-515.
17. Kim D.W., et al. The RelA NF-kappaB subunit and the aryl hydrocarbon receptor (AhR) cooperate to transactivate the c-myc promoter in mammary cells. Oncogene 2000, 19(48):5498-5506.
18. Puga A., et al. Role of the aryl hydrocarbon receptor in cell cycle regulation. Toxicology 2002, 181-182:171-177.
19. Andreola F., et al. Aryl hydrocarbon receptor knockout mice (AHR-/-) exhibit liver retinoid accumulation and reduced retinoic acid metabolism. Cancer Res. 1997, 57(14):2835-2838.
20. Morrow D., et al. Aryl hydrocarbon receptor-mediated inhibition of LNCaP prostate cancer cell growth and hormone-induced transactivation. J. Steroid Biochem. Mol. Biol. 2004, 88(1):27-36.
21. Kuil C.W., et al. Interference between progesterone and dioxin signal transduction pathways. Different mechanisms are involved in repression by the progesterone receptor A and B isoforms. J. Biol. Chem. 1998, 273(15):8829-8834.
22. Builee T.L., Hatherill J.R. The role of polyhalogenated aromatic hydrocarbons on thyroid hormone disruption and cognitive function: a review. Drug Chem. Toxicol. 2004, 27(4):405-424.
23. Iwano S., et al. CYP1A1-mediated mechanism for atherosclerosis induced by polycyclic aromatic hydrocarbons. Biochem. Biophys. Res. Commun. 2005, 337(2):708-712.
24. Klinge C.M., Kaur K., Swanson H.I. The aryl hydrocarbon receptor interacts with estrogen receptor alpha and orphan receptors COUP-TFI and ERRalpha1. Arch. Biochem. Biophys. 2000, 373(1):163-174.
25. Safe S., Wormke M. Inhibitory aryl hydrocarbon receptor-estrogen receptor alpha cross-talk and mechanisms of action. Chem. Res. Toxicol. 2003, 16(7):807-816.
26. Matthews J., Gustafsson J.A. Estrogen receptor and aryl hydrocarbon receptor signaling pathways. Nucl. Recept. Signal. 2006, 4:e016.
27. Bandiera S., Safe S., Okey A.B. Binding of polychlorinated biphenyls classified as either phenobarbitone-, 3-methylcholanthrene- or mixed-type inducers to cytosolic Ah receptor. Chem. Biol. Interact. 1982, 39(3):259-277.
28. IARC Polychlorinated Dibenzo-Para-Dioxins and Polychlorinated Dibenzofurans 1997, vol. 69:137-195. IARC Press, Lyon, France.
29. Safe S. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicol. Lett. 2001, 120(1-3):1-7.
30. Steenland K., et al. Dioxin revisited: developments since the 1997 IARC classification of dioxin as a human carcinogen. Environ. Health Perspect. 2004, 112(13):1265-1268.
31. EPA U. Dioxin Reassessment: Draft Exposure and Human Health Reassessment of 2,3,7,8-Tetrachlorodibenzo-p-Dioxin (TCDD) and Related Compounds. Part II: Health Assessment of TCDD and Related Compounds 2004, U.S. Environmental Protection Agency, Washington, DC, National Academy of Sciences (NAS) Review Draft 200. EPA/600/P-00/001Cb.
32. Liem A.K., Furst P., Rappe C. Exposure of populations to dioxins and related compounds. Food Addit. Contam. 2000, 17(4):241-259.
33. Jeuken A., et al. Activation of the Ah receptor by extracts of dietary herbal supplements, vegetables, and fruits. J. Agric. Food Chem. 2003, 51(18):5478-5487.
34. Bjeldanes L.F., et al. Aromatic hydrocarbon responsiveness-receptor agonists generated from indole-3-carbinol in vitro and in vivo: comparisons with 2,3,7,8-tetrachlorodibenzo-p-dioxin. Proc. Natl. Acad. Sci. U. S. A. 1991, 88(21):9543-9547.
35. Vivar O.I., et al. Selective activation of estrogen receptor-{beta} target genes by 3,3'-diindolylmethane. Endocrinology 2010, 151(4):1662-1667.
36. Riby J.E., et al. Ligand-independent activation of estrogen receptor function by 3, 3'-diindolylmethane in human breast cancer cells. Biochem. Pharmacol. 2000, 60(2):167-177.
37. Pohjanvirta R., et al. Comparison of acute toxicities of indolo[3,2-b]carbazole (ICZ) and 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in TCDD-sensitive rats. Food Chem. Toxicol. 2002, 40(7):1023-1032.
38. Bock K.W., Kohle C. Ah receptor: dioxin-mediated toxic responses as hints to deregulated physiologic functions. Biochem. Pharmacol. 2006, 72(4):393-404.
39. Athar M., et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol. Appl. Pharmacol. 2007, 224(3):274-283.
40. Signorelli P., Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J. Nutr. Biochem. 2005, 16(8):449-466.
41. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339(8808):1523-1526.
42. Ciolino H.P., Daschner P.J., Yeh G.C. Resveratrol inhibits transcription of CYP1A1 in vitro by preventing activation of the aryl hydrocarbon receptor. Cancer Res. 1998, 58(24):5707-5712.
43. Macpherson L., Matthews J. Inhibition of aryl hydrocarbon receptor-dependent transcription by resveratrol or kaempferol is independent of estrogen receptor alpha expression in human breast cancer cells. Cancer Lett. 2010, 299(2):119-129.
44. Gehm B.D., et al. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc. Natl. Acad. Sci. U. S. A. 1997, 94(25):14138-14143.
45. Ciolino H.P., Yeh G.C. Inhibition of aryl hydrocarbon-induced cytochrome P-450 1A1 enzyme activity and CYP1A1 expression by resveratrol. Mol. Pharmacol. 1999, 56(4):760-767.
46. Nijveldt R.J., et al. Flavonoids: a review of probable mechanisms of action and potential applications. Am. J. Clin. Nutr. 2001, 74(4):418-425.
47. Moon Y.J., Wang X., Morris M.E. Dietary flavonoids: effects on xenobiotic and carcinogen metabolism. Toxicol. In Vitro 2006, 20(2):187-210.
48. Ashida H., Nishiumi S., Fukuda I. An update on the dietary ligands of the AhR. Expert Opin. Drug Metab. Toxicol. 2008, 4(11):1429-1447.
49. Scalbert A., Williamson G. Dietary intake and bioavailability of polyphenols. J. Nutr. 2000, 130(8S Suppl.):2073S-2085S.
50. Ciolino H.P., Daschner P.J., Yeh G.C. Dietary flavonols quercetin and kaempferol are ligands of the aryl hydrocarbon receptor that affect CYP1A1 transcription differentially. Biochem. J. 1999, 340(Pt 3):715-722.
51. Tilg H. Diet and intestinal immunity. N. Engl. J. Med. 2012, 366(2):181-183.
52. Fernandez-Salguero P., et al. Immune system impairment and hepatic fibrosis in mice lacking the dioxin-binding Ah receptor. Science 1995, 268(5211):722-726.
53. Campbell S.J., et al. The murine Cyp1a1 gene is expressed in a restricted spatial and temporal pattern during embryonic development. J. Biol. Chem. 2005, 280(7):5828-5835.
54. Barhoover M.A., et al. Aryl hydrocarbon receptor regulates cell cycle progression in human breast cancer cells via a functional interaction with cyclin-dependent kinase 4. Mol. Pharmacol. 2010, 77(2):195-201.
55. Rannug A., et al. Certain photooxidized derivatives of tryptophan bind with very high affinity to the Ah receptor and are likely to be endogenous signal substances. J. Biol. Chem. 1987, 262(32):15422-15427.
56. Wincent E., et al. The suggested physiologic aryl hydrocarbon receptor activator and cytochrome P4501 substrate 6-formylindolo[3,2-b]carbazole is present in humans. J. Biol. Chem. 2009, 284(5):2690-2696.
57. Hankinson O. The aryl hydrocarbon receptor complex. Annu. Rev. Pharmacol. Toxicol. 1995, 35:307-340.
58. Pandini A., et al. Detection of the TCDD binding-fingerprint within the Ah receptor ligand binding domain by structurally driven mutagenesis and functional analysis. Biochemistry 2009, 48(25):5972-5983.
59. Denis M., et al. Association of the dioxin receptor with the Mr 90,000 heat shock protein: a structural kinship with the glucocorticoid receptor. Biochem. Biophys. Res. Commun. 1988, 155(2):801-807.
60. Perdew G.H. Association of the Ah receptor with the 90-kDa heat shock protein. J. Biol. Chem. 1988, 263(27):13802-13805.
61. Carver L.A., Bradfield C.A. Ligand-dependent interaction of the aryl hydrocarbon receptor with a novel immunophilin homolog in vivo. J. Biol. Chem. 1997, 272(17):11452-11456.
62. MacPherson L., et al. 2,3,7,8-Tetrachlorodibenzo-p-dioxin poly(ADP-ribose) polymerase (TiPARP, ARTD14) is a mono-ADP-ribosyltransferase and repressor of aryl hydrocarbon receptor transactivation. Nucleic Acids Res. 2013, 41(3):1604-1621.
63. Pollenz R.S. The mechanism of AH receptor protein down-regulation (degradation) and its impact on AH receptor-mediated gene regulation. Chem. Biol. Interact. 2002, 141(1-2):41-61.
64. Whitlock J.P. Induction of cytochrome P4501A1. Annu. Rev. Pharmacol. Toxicol. 1999, 39:103-125.
65. Poland A., Glover E. Comparison of 2,3,7,8-tetrachlorodibenzo-p-dioxin, a potent inducer of aryl hydrocarbon hydroxylase, with 3-methylcholanthrene. Mol. Pharmacol. 1974, 10(2):349-359.
66. Ma Q., et al. TCDD-inducible poly(ADP-ribose) polymerase: a novel response to 2,3,7,8-tetrachlorodibenzo-p-dioxin. Biochem. Biophys. Res. Commun. 2001, 289(2):499-506.
67. Matthews J., et al. Aryl hydrocarbon receptor-mediated transcription: ligand-dependent recruitment of estrogen receptor alpha to 2,3,7,8-tetrachlorodibenzo-p-dioxin-responsive promoters. Mol. Cell Biol. 2005, 25(13):5317-5328.
68. Ahmed S., et al. Dioxin increases the interaction between aryl hydrocarbon receptor and estrogen receptor alpha at human promoters. Toxicol. Sci. 2009, 111(2):254-266.
69. Lo R., Matthews J. High-resolution genome-wide mapping of AHR and ARNT binding sites by ChIP-Seq. Toxicol. Sci. 2012, 130(2):349-361.
70. Matsumura F. The significance of the nongenomic pathway in mediating inflammatory signaling of the dioxin-activated Ah receptor to cause toxic effects. Biochem. Pharmacol. 2009, 77(4):608-626.
71. Vogel C.F., et al. Pathogenesis of aryl hydrocarbon receptor-mediated development of lymphoma is associated with increased cyclooxygenase-2 expression. Am. J. Pathol. 2007, 171(5):1538-1548.
72. Pollenz R.S., Buggy C. Ligand-dependent and -independent degradation of the human aryl hydrocarbon receptor (hAHR) in cell culture models. Chem. Biol. Interact. 2006, 164(1-2):49-59.
73. Jin U.H., Lee S.O., Safe S. Aryl hydrocarbon receptor (AHR)-active pharmaceuticals are selective AHR modulators in MDA-MB-468 and BT474 breast cancer cells. J. Pharmacol. Exp. Ther. 2012, 343(2):333-341.
74. Mimura J., et al. Identification of a novel mechanism of regulation of Ah (dioxin) receptor function. Genes Dev. 1999, 13(1):20-25.
75. Mimura J., Fujii-Kuriyama Y. Functional role of AhR in the expression of toxic effects by TCDD. Biochim. Biophys. Acta 2003, 1619(3):263-268.
76. Evans B.R., et al. Repression of aryl hydrocarbon receptor (AHR) signaling by AHR repressor: role of DNA binding and competition for AHR nuclear translocator. Mol. Pharmacol. 2008, 73(2):387-398.
77. Kanno Y., et al. Suppressive effect of aryl hydrocarbon receptor repressor on transcriptional activity of estrogen receptor alpha by protein-protein interaction in stably and transiently expressing cell lines. Mol. Cell. Endocrinol. 2008, 291(1-2):87-94.
78. Hassa P.O., et al. Nuclear ADP-ribosylation reactions in mammalian cells: where are we today and where are we going?. Microbiol. Mol. Biol. 2006, 70(3):789-829.
79. Bunger M.K., et al. Abnormal liver development and resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity in mice carrying a mutation in the DNA-binding domain of the aryl hydrocarbon receptor. Toxicol. Sci. 2008, 106(1):83-92.
80. Bunger M.K., et al. Resistance to 2,3,7,8-tetrachlorodibenzo-p-dioxin toxicity and abnormal liver development in mice carrying a mutation in the nuclear localization sequence of the aryl hydrocarbon receptor. J. Biol. Chem. 2003, 278(20):17767-17774.
81. Poland A., Knutson J.C. 2,3,7,8-Tetrachlorodibenzo-p-dioxin and related halogenated aromatic hydrocarbons: examination of the mechanism of toxicity. Annu. Rev. Pharmacol. Toxicol. 1982, 22:517-554.
82. Tuomisto J.T., et al. TCDD-induced anorexia and wasting syndrome in rats: effects of diet-induced obesity and nutrition. Pharmacol. Biochem. Behav. 1999, 62(4):735-742.
83. Diani-Moore S., et al. Identification of the aryl hydrocarbon receptor target gene TiPARP as a mediator of suppression of hepatic gluconeogenesis by 2,3,7,8-tetrachlorodibenzo-p-dioxin and of nicotinamide as a corrective agent for this effect. J. Biol. Chem. 2010, 285(50):38801-38810.
84. Safe S.H. Development validation and problems with the toxic equivalency factor approach for risk assessment of dioxins and related compounds. J. Anim. Sci. 1998, 76(1):134-141.
85. Marlowe J.L., Puga A. Aryl hydrocarbon receptor, cell cycle regulation, toxicity, and tumorigenesis. J. Cell. Biochem. 2005, 96(6):1174-1184.
86. Panteleyev A.A., Bickers D.R. Dioxin-induced chloracne-reconstructing the cellular and molecular mechanisms of a classic environmental disease. Exp. Dermatol. 2006, 15(9):705-730.
87. Crump K.S., Canady R., Kogevinas M. Meta-analysis of dioxin cancer dose response for three occupational cohorts. Environ. Health Perspect. 2003, 111(5):681-687.
88. Kang H., et al. Soft tissue sarcoma and military service in Vietnam: a case-control study. J. Natl. Cancer Inst. 1987, 79(4):693-699.
89. Warner M., et al. Serum dioxin concentrations and breast cancer risk in the Seveso Women's Health Study. Environ. Health Perspect. 2002, 110(7):625-628.
90. Mocarelli P., et al. Dioxin exposure, from infancy through puberty, produces endocrine disruption and affects human semen quality. Environ. Health Perspect. 2008, 116(1):70-77.
91. Nebert D.W., et al. Role of aryl hydrocarbon receptor-mediated induction of the CYP1 enzymes in environmental toxicity and cancer. J. Biol. Chem. 2004, 279(23):23847-23850.
92. Park J.H., et al. Aryl hydrocarbon receptor facilitates DNA strand breaks and 8-oxo-2'-deoxyguanosine formation by the aldo-keto reductase product benzo[a]pyrene-7,8-dione. J. Biol. Chem. 2009, 284(43):29725-29734.
93. Lahvis G.P., Bradfield C.A. Ahr null alleles: distinctive or different?. Biochem. Pharmacol. 1998, 56(7):781-787.
94. Lahvis G.P., et al. The aryl hydrocarbon receptor is required for developmental closure of the ductus venosus in the neonatal mouse. Mol. Pharmacol. 2005, 67(3):714-720.
95. Harstad E.B., et al. Liver deformation in Ahr-null mice: evidence for aberrant hepatic perfusion in early development. Mol. Pharmacol. 2006, 69(5):1534-1541.
96. Abbott B.D., et al. Adverse reproductive outcomes in the transgenic Ah receptor-deficient mouse. Toxicol. Appl. Pharmacol. 1999, 155(1):62-70.
97. Puga A., Xia Y., Elferink C. Role of the aryl hydrocarbon receptor in cell cycle regulation. Chem. Biol. Interact. 2002, 141(1-2):117-130.
98. Abdelrahim M., Smith R., Safe S. Aryl hydrocarbon receptor gene silencing with small inhibitory RNA differentially modulates Ah-responsiveness in MCF-7 and HepG2 cancer cells. Mol. Pharmacol. 2003, 63(6):1373-1381.
99. Chopra M., Schrenk D. Dioxin toxicity, aryl hydrocarbon receptor signaling, and apoptosis-persistent pollutants affect programmed cell death. Crit. Rev. Toxicol. 2011, 41(4):292-320.
100. Elizondo G., et al. Altered cell cycle control at the G(2)/M phases in aryl hydrocarbon receptor-null embryo fibroblast. Mol. Pharmacol. 2000, 57(5):1056-1063.
101. Oberhammer F.A., et al. Induction of apoptosis in cultured hepatocytes and in regressing liver by transforming growth factor beta 1. Proc. Natl. Acad. Sci. U. S. A. 1992, 89(12):5408-5412.
102. Ma Q., Whitlock J.P. The aromatic hydrocarbon receptor modulates the Hepa 1c1c7 cell cycle and differentiated state independently of dioxin. Mol. Cell Biol. 1996, 16(5):2144-2150.
103. Spink B.C., et al. Expression of the aryl hydrocarbon receptor is not required for the proliferation, migration, invasion, or estrogen-dependent tumorigenesis of MCF-7 breast cancer cells. Mol. Carcinog. 2012, 1(1).
104. Ciolino H.P., Dankwah M., Yeh G.C. Resistance of MCF-7 cells to dimethylbenz(a)anthracene-induced apoptosis is due to reduced CYP1A1 expression. Int. J. Oncol. 2002, 21(2):385-391.
105. Kolluri S.K., et al. p27(Kip1) induction and inhibition of proliferation by the intracellular Ah receptor in developing thymus and hepatoma cells. Genes Dev. 1999, 13(13):1742-1753.
106. Elferink C.J., Ge N.L., Levine A. Maximal aryl hydrocarbon receptor activity depends on an interaction with the retinoblastoma protein. Mol. Pharmacol. 2001, 59(4):664-673.
107. Marlowe J.L., et al. The aryl hydrocarbon receptor displaces p300 from E2F-dependent promoters and represses S phase-specific gene expression. J. Biol. Chem. 2004, 279(28):29013-29022.
108. Kerkvliet N.I. Immunological effects of chlorinated dibenzo-p-dioxins. Environ. Health Perspect. 1995, 103(Suppl 9):47-53.
109. Boitano A.E., et al. Aryl hydrocarbon receptor antagonists promote the expansion of human hematopoietic stem cells. Science 2010, 329(5997):1345-1348.
110. Veldhoen M., et al. The aryl hydrocarbon receptor links TH17-cell-mediated autoimmunity to environmental toxins. Nature 2008, 453(7191):106-109.
111. Quintana F.J., et al. Control of T(reg) and T(H)17 cell differentiation by the aryl hydrocarbon receptor. Nature 2008, 453(7191):65-71.
112. Pot C. Aryl hydrocarbon receptor controls regulatory CD4+ T cell function. Swiss Med. Wkly. 2012, 142:w13592.
113. Couse J.F., Korach K.S. Estrogen receptor null mice: what have we learned and where will they lead us?. Endocr. Rev. 1999, 20(3):358-417.
114. McLachlan J.A., Simpson E., Martin M. Endocrine disrupters and female reproductive health. Best Pract. Res. Clin. Endocrinol. Metab. 2006, 20(1):63-75.
115. Carlsen E., et al. Decreasing quality of semen. BMJ 1993, 306(6875):461.
116. Guillette L.J., et al. Developmental abnormalities of the gonad and abnormal sex hormone concentrations in juvenile alligators from contaminated and control lakes in Florida. Environ. Health Perspect. 1994, 102(8):680-688.
117. Kuiper G.G., et al. Cloning of a novel receptor expressed in rat prostate and ovary. Proc. Natl. Acad. Sci. U. S. A. 1996, 93(12):5925-5930.
118. Heldring N., et al. Estrogen receptors: how do they signal and what are their targets. Physiol. Rev. 2007, 87(3):905-931.
119. Matthews J., Gustafsson J.A. Estrogen signaling: a subtle balance between ER alpha and ER beta. Mol. Interv. 2003, 3(5):281-292.
120. Harris H.A. Estrogen receptor-beta: recent lessons from in vivo studies. Mol. Endocrinol. 2007, 21(1):1-13.
121. Murphy L.C., Watson P.H. Is oestrogen receptor-beta a predictor of endocrine therapy responsiveness in human breast cancer?. Endocr. Relat. Cancer 2006, 13(2):327-334.
122. Nilsson S., et al. Mechanisms of estrogen action. Physiol. Rev. 2001, 81(4):1535-1565.
123. Evans R.M. The steroid and thyroid hormone receptor superfamily. Science 1988, 240(4854):889-895.
124. Shang Y., et al. Cofactor dynamics and sufficiency in estrogen receptor-regulated transcription. Cell 2000, 103(6):843-852.
125. Metivier R., et al. Estrogen receptor-alpha directs ordered, cyclical, and combinatorial recruitment of cofactors on a natural target promoter. Cell 2003, 115(6):751-763.
126. Paech K., et al. Differential ligand activation of estrogen receptors ERalpha and ERbeta at AP1 sites. Science 1997, 277(5331):1508-1510.
127. Saville B., et al. Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J. Biol. Chem. 2000, 275(8):5379-5387.
128. Lonard D.M., et al. The 26S proteasome is required for estrogen receptor-alpha and coactivator turnover and for efficient estrogen receptor-alpha transactivation. Mol. Cell 2000, 5(6):939-948.
129. Reid G., et al. Cyclic, proteasome-mediated turnover of unliganded and liganded ERa on responsive promoters is an integral feature of estrogen signaling. Mol. Cell 2003, 11:695-707.
130. McKenna N.J., Lanz R.B., O'Malley B.W. Nuclear receptor coregulators: cellular and molecular biology. Endocr. Rev. 1999, 20(3):321-344.
131. Hu X., Lazar M.A. The CoRNR motif controls the recruitment of corepressors by nuclear hormone receptors. Nature 1999, 402(6757):93-96.
132. Heery D.M., et al. Core LXXLL motif sequences in CREB-binding protein, SRC1, and RIP140 define affinity and selectivity for steroid and retinoid receptors. J. Biol. Chem. 2001, 276(9):6695-6702.
133. Wittmann B.M., Sherk A., McDonnell D.P. Definition of functionally important mechanistic differences among selective estrogen receptor down-regulators. Cancer Res. 2007, 67(19):9549-9560.
134. Klinge C.M. Estrogen receptor interaction with estrogen response elements. Nucleic Acids Res. 2001, 29(14):2905-2919.
135. Lupien M., et al. FoxA1 translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell 2008, 132(6):958-970.
136. Hurtado A., et al. FOXA1 is a key determinant of estrogen receptor function and endocrine response. Nat. Genet. 2011, 43(1):27-33.
137. Friedman J.R., Kaestner K.H. The Foxa family of transcription factors in development and metabolism. Cell. Mol. Life Sci. 2006, 63(19-20):2317-2328.
138. Ahmed S., Al-Saigh S., Matthews J. FOXA1 is essential for aryl hydrocarbon receptor-dependent regulation of cyclin G2. Mol. Cancer Res. 2012, 10(5):636-648.
139. Bernardo G.M., et al. FOXA1 is an essential determinant of ERalpha expression and mammary ductal morphogenesis. Development 2010, 137(12):2045-2054.
140. Hoivik D., et al. Estrogen does not inhibit 2,3,7, 8-tetrachlorodibenzo-p-dioxin-mediated effects in MCF-7 and Hepa 1c1c7 cells. J. Biol. Chem. 1997, 272(48):30270-30274.
141. Kharat I., Saatcioglu F. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin are mediated by direct transcriptional interference with the liganded estrogen receptor. cross-talk between aryl hydrocarbon- and estrogen-mediated signaling. J. Biol. Chem. 1996, 271(18):10533-10537.
142. Kociba R.J., et al. Results of a two-year chronic toxicity and oncogenicity study of 2,3,7,8-tetrachlorodibenzo-p-dioxin in rats. Toxicol. Appl. Pharmacol. 1978, 46(2):279-303.
143. Wormke M., et al. Estrogen and aryl hydrocarbon receptor expression and crosstalk in human Ishikawa endometrial cancer cells. J. Steroid Biochem. Mol. Biol. 2000, 72(5):197-207.
144. Ohtake F., et al. Dioxin receptor is a ligand-dependent E3 ubiquitin ligase. Nature 2007, 446(7135):562-566.
145. Romkes M., Safe S. Comparative activities of 2,3,7,8-tetrachlorodibenzo-p-dioxin and progesterone as antiestrogens in the female rat uterus. Toxicol. Appl. Pharmacol. 1988, 92(3):368-380.
146. Boverhof D.R., et al. Inhibition of estrogen-mediated uterine gene expression responses by dioxin. Mol. Pharmacol. 2008, 73(1):82-93.
147. Buchanan D.L., et al. Antiestrogenic effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin in mouse uterus: critical role of the aryl hydrocarbon receptor in stromal tissue. Toxicol. Sci. 2000, 57(2):302-311.
148. Buchanan D.L., et al. Dioxin inhibition of estrogen-induced mouse uterine epithelial mitogenesis involves changes in cyclin and transforming growth factor-beta expression. Toxicol. Sci. 2002, 66(1):62-68.
149. Gierthy J.F., et al. Correlation of in vitro and in vivo growth suppression of MCF-7 human breast cancer by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Res. 1993, 53(13):3149-3153.
150. Holcomb M., Safe S. Inhibition of 7,12-dimethylbenzanthracene-induced rat mammary tumor growth by 2,3,7,8-tetrachlorodibenzo-p-dioxin. Cancer Lett. 1994, 82(1):43-47.
151. Wormke M., et al. The aryl hydrocarbon receptor mediates degradation of estrogen receptor alpha through activation of proteasomes. Mol. Cell Biol. 2003, 23(6):1843-1855.
152. Cavalieri E., et al. Estrogens as endogenous genotoxic agents-DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 2000, 27:75-93.
153. Cavalieri E., et al. Catechol estrogen quinones as initiators of breast and other human cancers: implications for biomarkers of susceptibility and cancer prevention. Biochim. Biophys. Acta 2006, 1766(1):63-78.
154. McDougal A., et al. Methyl-substituted diindolylmethanes as inhibitors of estrogen-induced growth of T47D cells and mammary tumors in rats. Breast Cancer Res. Treat. 2001, 66(2):147-157.
155. Krishnan V., et al. Molecular mechanism of inhibition of estrogen-induced cathepsin D gene expression by 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) in MCF-7 cells. Mol. Cell Biol. 1995, 15(12):6710-6719.
156. Shiverick K.T., Muther T.F. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin on serum concentrations and the uterotrophic action of exogenous estrone in rats. Toxicol. Appl. Pharmacol. 1982, 65(1):170-176.
157. Ohtake F., et al. Intrinsic AhR function underlies cross-talk of dioxins with sex hormone signalings. Biochem. Biophys. Res. Commun. 2008, 370(4):541-546.
158. Reen R.K., Cadwallader A., Perdew G.H. The subdomains of the transactivation domain of the aryl hydrocarbon receptor (AhR) inhibit AhR and estrogen receptor transcriptional activity. Arch. Biochem. Biophys. 2002, 408(1):93-102.
159. Madak-Erdogan Z., Katzenellenbogen B.S. Aryl hydrocarbon receptor modulation of estrogen receptor alpha-mediated gene regulation by a multimeric chromatin complex involving the two receptors and the coregulator RIP140. Toxicol. Sci. 2012, 125(2):401-411.
160. Brunnberg S., et al. The basic helix-loop-helix-PAS protein ARNT functions as a potent coactivator of estrogen receptor-dependent transcription. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(11):6517-6522.
161. Labrecque M.P., et al. Distinct roles for aryl hydrocarbon receptor nuclear translocator and ah receptor in estrogen-mediated signaling in human cancer cell lines. PLoS One 2012, 7(1):e29545.
162. Ruegg J., et al. The transcription factor aryl hydrocarbon receptor nuclear translocator functions as an estrogen receptor beta-selective coactivator, and its recruitment to alternative pathways mediates antiestrogenic effects of dioxin. Mol. Endocrinol. 2008, 22(2):304-316.
163. Rogers J.M., Denison M.S. Analysis of the antiestrogenic activity of 2,3,7,8-tetrachlorodibenzo-p-dioxin in human ovarian carcinoma BG-1 cells. Mol. Pharmacol. 2002, 61(6):1393-1403.
164. Ma Q. Induction and superinduction of 2,3,7,8-tetrachlorodibenzo-rho-dioxin-inducible poly(ADP-ribose) polymerase: role of the aryl hydrocarbon receptor/aryl hydrocarbon receptor nuclear translocator transcription activation domains and a labile transcription repressor. Arch. Biochem. Biophys. 2002, 404(2):309-316.
165. Harris M., Zacharewski T., Safe S. Effects of 2,3,7,8-tetrachlorodibenzo-p-dioxin and related compounds on the occupied nuclear estrogen receptor in MCF-7 human breast cancer cells. Cancer Res. 1990, 50(12):3579-3584.
166. Safe S., Wormke M., Samudio I. Mechanisms of inhibitory aryl hydrocarbon receptor-estrogen receptor crosstalk in human breast cancer cells. J. Mammary Gland Biol. Neoplasia 2000, 5(3):295-306.
167. Wijayaratne A.L., McDonnell D.P. The human estrogen receptor-alpha is a ubiquitinated protein whose stability is affected differentially by agonists, antagonists, and selective estrogen receptor modulators. J. Biol. Chem. 2001, 276(38):35684-35692.
168. Dusell C.D., et al. Regulation of aryl hydrocarbon receptor function by selective estrogen receptor modulators. Mol. Endocrinol. 2010, 24(1):33-46.
169. MacPherson L., et al. Activation function 2 mediates dioxin-induced recruitment of estrogen receptor alpha to CYP1A1 and CYP1B1. Biochem. Biophys. Res. Commun. 2009, 385(2):263-268.
170. Krishnan V., Wang X., Safe S. Estrogen receptor-Sp1 complexes mediate estrogen-induced cathepsin D gene expression in MCF-7 human breast cancer cells. J. Biol. Chem. 1994, 269(22):15912-15917.
171. Zacharewski T.R., et al. Antiestrogenic effect of 2,3,7,8-tetrachlorodibenzo-p-dioxin on 17 beta-estradiol-induced pS2 expression. Cancer Res. 1994, 54(10):2707-2713.
172. Beischlag T.V., Perdew G.H. ER alpha-AHR-ARNT protein-protein interactions mediate estradiol-dependent transrepression of dioxin-inducible gene transcription. J. Biol. Chem. 2005, 280(22):21607-21611.
173. Abdelrahim M., et al. 3-Methylcholanthrene and other aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha. Cancer Res. 2006, 66(4):2459-2467.
174. Ohtake F., et al. Modulation of oestrogen receptor signaling by association with the activated dioxin receptor. Nature 2003, 423(6939):545-550.
175. Boverhof D.R., et al. Dioxin induces an estrogen-like, estrogen receptor dependent gene expression response in the murine uterus. Mol. Pharmacol. 2006, 69(5):1599-1606.
176. Shipley J.M., Waxman D.J. Aryl hydrocarbon receptor-independent activation of estrogen receptor-dependent transcription by 3-methycholanthrene. Toxicol. Appl. Pharmacol. 2005, 213(2):87-97.
177. Weiss C., et al. Complementation of Ah receptor deficiency in hepatoma cells: negative feedback regulation and cell cycle control by the Ah receptor. Exp. Cell Res. 1996, 226(1):154-163.
178. Swedenborg E., et al. 3-Methylcholanthrene displays dual effects on estrogen receptor (ER) alpha and ER beta signaling in a cell-type specific fashion. Mol. Pharmacol. 2008, 73(2):575-586.
179. Fertuck K.C., Matthews J.B., Zacharewski T.R. Hydroxylated benzo[a]pyrene metabolites are responsible for in vitro estrogen receptor-mediated gene expression induced by benzo[a]pyrene, but do not elicit uterotrophic effects in vivo. Toxicol. Sci. 2001, 59(2):231-240.
180. Pearce S.T., et al. Interaction of the aryl hydrocarbon receptor ligand 6-methyl-1,3,8-trichlorodibenzofuran with estrogen receptor alpha. Cancer Res. 2004, 64(8):2889-2897.
181. Liu S., et al. Aryl hydrocarbon receptor agonists directly activate estrogen receptor alpha in MCF-7 breast cancer cells. Biol. Chem. 2006, 387(9):1209-1213.
182. Wihlen B., et al. Estrogen receptor subtype- and promoter-specific modulation of aryl hydrocarbon receptor-dependent transcription. Mol. Cancer Res. 2009, 7(6):977-986.
183. Safe S., McDougal A. Mechanism of action and development of selective aryl hydrocarbon receptor modulators for treatment of hormone-dependent cancers (Review). Int. J. Oncol. 2002, 20(6):1123-1128.
184. Santiago Y., et al. Targeted gene knockout in mammalian cells by using engineered zinc-finger nucleases. Proc. Natl. Acad. Sci. U. S. A. 2008, 105(15):5809-5814.
185. Boch J., et al. Breaking the code of DNA binding specificity of TAL-type III effectors. Science 2009, 326(5959):1509-1512.
186. Thomsen J.S., et al. Restoration of aryl hydrocarbon (Ah) responsiveness in MDA-MB-231 human breast cancer cells by transient expression of the estrogen receptor. Carcinogenesis 1994, 15(5):933-937.
187. Matthews J., et al. Co-planar 3,3',4,4',5-pentachlorinated biphenyl and non-co-planar 2,2',4,6,6'-pentachlorinated biphenyl differentially induce recruitment of oestrogen receptor alpha to aryl hydrocarbon receptor target genes. Biochem. J. 2007, 406(2):343-353.
188. Vickers P.J., Dufresne M.J., Cowan K.H. Relation between cytochrome P450IA1 expression and estrogen receptor content of human breast cancer cells. Mol. Endocrinol. 1989, 3(1):157-164.
189. Sladek N.E. Transient induction of increased aldehyde dehydrogenase 3A1 levels in cultured human breast (adeno)carcinoma cell lines via 5'-upstream xenobiotic, and electrophile, responsive elements is, respectively, estrogen receptor-dependent and -independent. Chem. Biol. Interact. 2003, 143-144:63-74.
190. Spink D.C., et al. Estrogen regulates Ah responsiveness in MCF-7 breast cancer cells. Carcinogenesis 2003, 24(12):1941-1950.
191. Sarkar S., et al. Estrogen enhances induction of cytochrome P-4501A1 by 2,3,7, 8-tetrachlorodibenzo-p-dioxin in liver of female Long-Evans rats. Int. J. Oncol. 2000, 16(1):141-147.
192. Spink B.C., et al. Long-term estrogen exposure promotes carcinogen bioactivation, induces persistent changes in gene expression, and enhances the tumorigenicity of MCF-7 human breast cancer cells. Toxicol. Appl. Pharmacol. 2009.
193. Ricci M.S., et al. Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. J. Biol. Chem. 1999, 274(6):3430-3438.
194. Tsuchiya Y., et al. Human CYP1B1 is regulated by estradiol via estrogen receptor. Cancer Res. 2004, 64(9):3119-3125.
195. Zhang S., et al. The aryl hydrocarbon receptor as a target for estrogen receptor-negative breast cancer chemotherapy. Endocr. Relat. Cancer 2009, 16(3):835-844.
196. Wang F., et al. Identification of a functional imperfect estrogen-responsive element in the 5'-promoter region of the human cathepsin D gene. Biochemistry 1997, 36(25):7793-7801.
197. Hall J.M., et al. Activation of the aryl-hydrocarbon receptor inhibits invasive and metastatic features of human breast cancer cells and promotes breast cancer cell differentiation. Mol. Endocrinol. 2010, 24(2):359-369.
198. Prud'homme G.J., et al. Breast cancer stem-like cells are inhibited by a non-toxic aryl hydrocarbon receptor agonist. PLoS One 2010, 5(11):e13831.
199. Whitacre C.C. Sex differences in autoimmune disease. Nat. Immunol. 2001, 2(9):777-780.
200. Bebo B.F., et al. Androgens alter the cytokine profile and reduce encephalitogenicity of myelin-reactive T cells. J. Immunol. 1999, 162(1):35-40.
201. Polanczyk M., et al. Estrogen receptor-1 (Esr1) and -2 (Esr2) regulate the severity of clinical experimental allergic encephalomyelitis in male mice. Am. J. Pathol. 2004, 164(6):1915-1924.
202. Holmdahl R., Jansson L., Andersson M. Female sex hormones suppress development of collagen-induced arthritis in mice. Arthritis Rheum. 1986, 29(12):1501-1509.
203. Lahoti T.S., et al. Aryl hydrocarbon receptor antagonism mitigates cytokine-mediated inflammatory signaling in primary human fibroblast-like synoviocytes. Ann. Rheum. Dis. 2013.